Navigation Links
Sunesis Reports Financial Results for the First Quarter 2009
Date:5/6/2009

enerally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

About Ovarian Cancer

In the United States, ovarian cancer remains the leading cause of death from gynecologic malignancies and is the fifth leading cause of cancer death overall in women behind lung, breast, colorectal and pancreatic cancers. According to the American Cancer Society, in 2008 there were an estimated 21,650 new cases and more than 15,000 deaths from ovarian cancer in the U.S. alone. Following frontline treatment, recurrence rates among ovarian cancer patients are high. Treatment options remain limited following relapse, and overall long-term survival has not changed significantly over the past 40 years, with five-year survival rates at less than 30 percent.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.

This press release contains forward-looking statements, including without limitation statements related to the potential safety and efficacy and commercial potential of voreloxin, the completion of the tranched financing, the activity of vorelox
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
2. Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350
3. Sunesis Pharmaceuticals SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology
4. Sunesis Pharmaceuticals to Present at Healthcare Investor Conferences in March
5. Sunesis Pharmaceuticals Presents Nonclinical Data on SNS-595 at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
7. Sunesis Pharmaceuticals to Present at the Collins Stewart Fourth Annual Growth Conference
8. Sunesis Pharmaceuticals Announces Up To $43.5 Million Financing
9. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
10. Haemacure Reports Third Quarter 2007 Results
11. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... For the first time, researchers have access to detailed ... uses health care. A new study, called Our Health ... unique challenges faced by urban Aboriginal people in Canada ... , The findings, published today in BMJ Open ... and the general population. , Researchers interviewed 554 First ...
(Date:7/9/2014)... hidden ways that cells are regulated, scientists at Rockefeller ... cells more likely to metastasize. , What,s more, the ... blocking two other proteins that are normally linked to ... could have unexpected ties. , The study, which ... , points to the possibility of new cancer therapies ...
(Date:7/9/2014)... in policing injection drug users in Russia might ... , A study, conducted by researchers from Boston ... collaboration with St. Petersburg Pavlov State University, sought ... the health outcomes of a cohort of HIV-positive ... Those who were arrested by police were more ...
(Date:7/9/2014)... YORK (July 8, 2014) Researchers from Montefiore ... of Medicine of Yeshiva University will present new ... held July 12 July 17 in Copenhagen, Denmark. ... that could prompt transition from cognitive normality to mild ... the Einstein Aging Study , established in 1980 ...
(Date:7/9/2014)... The liver is one of the most important organs ... that we utilize our food properly this is ... removed from our organism this is its detoxification ... and unhealthy food all damage the liver. The resulting ... deposits, cirrhoses, and life-threatening liver failure. According to the ...
Breaking Medicine News(10 mins):Health News:Urban Aboriginal people face unique health challenges 2Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:BU researchers relate arrests with HIV risk environment 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3
... 3, 2007) Two methods that permit scientists ... in this months release of Cold Spring Harbor ... online ( www.cshprotocols.org ), describe how to fluorescently tag ... combined with sophisticated imaging methods, permit scientists to visualize ...
... with Las Vegas and Tucson Marathon Runners, PLEASANT ... an event to prevent inflammation and pain, but at ... by researchers at,Appalachian State University and Vanderbilt University, published ... taking ibuprofen,before exercise may be unhealthy in the long ...
... to,build on the issue of requiring physicians to ... Management Association,(PCMA) today announced a new round of ... Last year, Dr. Bootman co-chaired an Institute of ... using e-prescribing by,2010 to help reduce the estimated ...
... ... -, JEFFERSON CITY, Mo., ... -,Missouri Military Family Relief Fund, which will help support the needs of,more than ... for the central market area at,TriWest, will present the check to the Adjutant ...
... Dec. 3 Operon,Biotechnologies, Eurofins MWG and Eurofins ... - announced today that they have agreed to ... leader in the competitive,custom oligonucleotide market. With about ... high-throughput production facilities in all major markets (North,America, ...
... retires; Mike Gallagher, President and CEO of ... Dec. 3 AvMed Health Plans said today ... to retire December 31,2007. As a result, Mike ... HealthCare, who already has overall leadership and strategic,responsibilities ...
Cached Medicine News:Health News:Cold Spring Harbor Protocols features innovative methods for embryology research 2Health News:Marathoners Share Tom Brady and LaDainian Tomlinson Pain Relief Affinity 2Health News:TriWest Contributes $15,000 to Missouri National Guard Fund 2Health News:MWG and Operon Are Joining Forces 2Health News:AvMed Announces Senior Leadership Changes 2
(Date:1/15/2014)... to Millennium Research Group (MRG), the global authority ... United States and European transcatheter embolization ... through 2022, with embolization particles representing one of ... drug-eluting beads (DEBs) and radioembolization spheres in interventional ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Global ... Systems -- Focus on End Users ... OBJECTIVES A drug delivery system ...
(Date:1/14/2014)... Mass. , Jan. 14, 2014 HeartWare ... leading innovator of less invasive, miniaturized circulatory support technologies ... today announced that it expects revenues for the fourth ... expected full-year 2013 revenues to approximately $208 million. ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... PHILADELPHIA, Jan. 20, 2011 The U.S. Food ... System Drugs Advisory Committee decided today that it ... this time based on the currently available data ... of Amyvid conditional on a reader training program ...
... Inc. (Nasdaq: ELGX ), developer of minimally invasive ... release of its fourth quarter and full year 2010 financial ... after the close of the market. Endologix will ... 5:00 p.m. ET / 2:00 p.m. PT to discuss the ...
Cached Medicine Technology:Statement from Lilly and Avid on FDA Advisory Committee Recommendation for Amyvid™ (Florbetapir) NDA 2Endologix to Report Fourth Quarter and Full Year 2010 Financial Results on February 22, 2011 2
For use with cushioned neckband....
... PVC siliconized. Stainless steel spiral reinforced. X-ray ... use. Adjustable Flange: The flange can be ... the thickness of the cervical soft tissue. ... the flange is tightly connected to the ...
... The permanent flexible tube ... of the neck flange helps ... neck, chin, and stoma, enhancing ... ,Bivona® FlexTend™ tracheostomy tubes ...
Aire-Cuf® tracheostomy tubes are ideal for short-term to medium-term ventilator support....
Medicine Products: